{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 2 of 2 results
Status:
Possibly Marketed Outside US
Source:
M028
(2023)
Source URL:
First approved in 2023
Source:
Rhinitis Yituling by Sanfutang Traditional Chinese Medicine Investment (Yunnan) Co., Ltd
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M028
(2023)
Source URL:
First approved in 2020
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE